Such an advancement would allow for one of the most successful non-chemo cancer treatments to be done both faster and cheaper ...

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...

When killer T cells of our immune system divide, they normally undergo asymmetric cell division (ACD): Each daughter cell ...

Universal CAR T cells produce rapid remissions and enable allogeneic stem cell transplants in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.

In a person living with HIV, proviruses—strands of HIV DNA—are typically integrated into the T cell genome and become a ...

An expert discusses IL-18-armored CAR T cells for adults with relapsed B-cell leukemia, showing complete remissions with ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Antigen-driven TCR signaling in the epidermis during CD8+ TRM differentiation results in a lower TGFβ requirement for persistence and increased proliferative capacity that together enhance epidermal ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...